DrugPatentWatch Database Preview
Drugs in Development Information for Evobrutinib
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug Evobrutinib?
Evobrutinib is an investigational drug.
There have been 8 clinical trials for Evobrutinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 19th 2019.
The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and Multiple Sclerosis. The leading clinical trial sponsors are Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc., and Merck KGaA.
There are four US patents protecting this investigational drug and thirty international patents.
Summary for Evobrutinib
| US Patents | 4 |
| International Patents | 30 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-08-19) |
| Vendors | 19 |
Recent Clinical Trials for Evobrutinib
| Title | Sponsor | Phase |
|---|---|---|
| Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) | Merck KGaA, Darmstadt, Germany | Phase 3 |
| Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) | EMD Serono Research & Development Institute, Inc. | Phase 3 |
Clinical Trial Summary for Evobrutinib
Top disease conditions for Evobrutinib
Top clinical trial sponsors for Evobrutinib
US Patents for Evobrutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Evobrutinib | Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| Evobrutinib | Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| Evobrutinib | Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| Evobrutinib | Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Evobrutinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Evobrutinib | Australia | 2012267491 | 2031-06-10 | Start Trial |
| Evobrutinib | Australia | 2017235978 | 2031-06-10 | Start Trial |
| Evobrutinib | Brazil | 112013030442 | 2031-06-10 | Start Trial |
| Evobrutinib | Canada | 2833771 | 2031-06-10 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
